Study S001354

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05646706
Acronym: STEP UP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 1407
Start: 2023-01-04
Primary completion: 2024-10-30
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1274-4259; EUDRACT_NUMBER:2022-000790-94

Registered primary outcomes

Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight [Baseline (week 0), End of treatment (week 72)]
Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no) [At week 72]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012383	Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Hjelmesæth J, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42764399 DOI	cites ClinicalTrials.gov:NCT05646706; registry reference DERIVED:42764399
R0053022	2829-LB: STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets CAREL LE ROUX, Diabetes	2026	Other trial	DOI	cites ClinicalTrials.gov:NCT05646706
R0016489	Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Wharton S, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40961952 DOI	cites ClinicalTrials.gov:NCT05646706; registry reference DERIVED:40961952
R0038036	1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial Sean Wharton, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05646706